SM-102 [2089251-47-6]
Referência T9410-100mg
Tamanho : 100mg
Marca : TargetMol
SM-102
SM-102
Copy Product Info
Cas No. 2089251-47-6
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.74%
Color:Transparent to Orange
COA HNMR LCMS
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | SM-102 is the only ionizable amino cationic lipid currently clinically approved for RNA therapeutics and can be used to synthesize lipid nanoparticles (LNPs). It shows potential in the development of LNPs for the delivery of mRNA-based vaccines. |
| Targets&IC50 | IK (erg) (MA-10 cells):98 μM, IK (erg):108 μM |
| In vitro | METHODS: The effects of SM-102 on ionic currents in two endocrine cells, rat pituitary tumor (GH3) cells and mouse Leydig tumor (MA-10) cells, or microglial cells (BV2), were investigated. Hyperpolarization-activated K currents in these cells bathed in a high-K, Ca2+-free extracellular solution were examined to assess the effects of SM-102 on the amplitude and hysteresis of erg-mediated K currents (I+K(erg)). RESULTS The addition of SM-102 effectively blocked IK(erg) in a concentration-dependent manner with a half-peak concentration (IC50) of 108 μM, which was similar to the KD value required for its enhanced current inactivation time constant (i.e., 134 μM); in the presence of SM-102, exposure of cells to the transfection reagent TurboFectinTM 8.0 (0.1%, v/v) was able to effectively inhibit hyperpolarization-activated IK(erg) and increase the inactivation time course of the current; in addition, in GH3 cells dialyzed with spermine (30 μM), the amplitude of IK(erg) gradually decreased; further use of SM-102 (100 μM) or TurboFectin (0.1%) further reduced the current amplitude; in MA-10 Leydig cells, the IC50 value of SM-102-induced IK(erg) inhibition in MA-10 cells was 98 μM. In BV2 microglia, the amplitude of inwardly rectifying K currents is inhibited by SM-102.[3] |
| Molecular Weight | 710.17 |
| Formula | C44H87NO5 |
| Cas No. | 2089251-47-6 |
| Smiles | CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC |
| Relative Density. | 0.925 g/cm3 (Predicted) |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (77.45 mM), Sonication is recommended.  Ethanol: 100 mg/mL (140.81 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.82 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Ethanol
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||